The MRAD9 Radioresistance Gene

MRAD9 放射抗性基因

基本信息

项目摘要

DESCRIPTION (provided by applicant): The way organisms respond to radiation exposure is important since induced DNA lesions can lead to mutation, genomic instability, and death, cancer or other deleterious health problems. Previous efforts of ours have focused on fission yeast S. pombe rad9, a gene that promotes gamma-ray resistance, UV-resistance, resistance to the DNA replication inhibitor hydroxyurea, and regulates the associated cell cycle checkpoints. We identified human (HRAD9) and mouse (Mrad9) orthologues, and the corresponding cDNAs were found to partially complement several defects demonstrated by rad9::ura4+ yeast. Furthermore, we found that HRAD9 protein binds the checkpoint proteins HHUS1 and HRAD1 at its C-terminal region, and contains a BH3-like domain at its N-terminal region that can bind the anti-apoptotic proteins BCL-2 and BCL-xL, and can cause apoptosis when overexpressed. We also found that this multifunctional Rad9 protein can bind p53 and co- regulate p21. Recent studies indicate that Rad9 also participates in multiple DNA repair pathways as well. We found that Rad9 physically interacts with Rad51 and functions in homologous recombination repair, and others reported that Rad9 can bind and regulate the activity of several proteins involved in base excision repair and mismatch repair. Interestingly, we identified structurally and functionally similar paralogues of Rad9, which we call HRAD9B (human) and Mrad9B (mouse), indicating that Rad9 is part of a gene family. We constructed Mrad9 and Mrad9B knockout cells and mice and found that both genes are essential for embryogenesis. Moreover, based on several established functions of Rad9, such as roles in maintaining genomic stability and homologous recombination, which are critical for spermatogenesis, we investigated whether Rad9 functions in this process. We now provide novel preliminary data indicating that we constructed mice bearing a targeted deletion of Mrad9 in early lineage spermatogonia, type A, and that these animals in fact demonstrate defects in spermatogenesis. The major focus of this proposal builds on and extends our findings to study Rad9 function. Specifically, we will make use of Mrad9 knockout cells and mice we constructed to address focused hypotheses designed to elucidate the mechanisms by which the gene maintains genomic stability, promotes resistance to DNA damage, and regulates spermatogenesis. These hypotheses include: 1) Mrad9 promotes genomic stability and cellular resistance to DNA damage by regulating specific DNA repair pathways and cell cycle checkpoints; and 2) Mrad9 plays an important role in spermatogenesis and in the meiotic cell cycle by regulating genomic stability, apoptosis and repair in testis. These studies will examine Mrad9 function from molecular to cellular to whole animal levels. In addition, this investigation could impact on a wide array of important issues, including understanding inherent susceptibility to DNA damage, with implications for radiotherapy, as well as the genetic control of sperm development and male infertility.
描述(由申请人提供):生物体对辐射暴露的反应方式很重要,因为诱导的DNA病变会导致突变,基因组不稳定性和死亡,癌症或其他有害健康问题。我们的先前努力集中在裂变酵母S. pombe rad9上,该基因促进了伽马射线耐药性,抗紫外线抗性,对DNA复制抑制剂羟基脲的耐药性,并调节相关的细胞周期检查点。我们确定了人(HRAD9)和小鼠(MRAD9)直系同源物,发现相应的cDNA部分补充了Rad9 :: ura4+酵母所证明的几种缺陷。此外,我们发现HRAD9蛋白在其C末端区域结合了检查点蛋白HHUS1和HRAD1,并在其N末端区域包含一个类似BH3的结构域,可以结合抗凋亡蛋白Bcl-2和Bcl-XL,并可能导致过度表达的凋亡。我们还发现,这种多功能RAD9蛋白可以结合p53并共同调节p21。最近的研究表明,RAD9也参与了多个DNA修复途径。我们发现RAD9与RAD51物理相互作用以及在同源重组修复中的功能,而其他人则报告说,Rad9可以结合和调节几种涉及基础切除修复和不匹配修复的蛋白质的活性。有趣的是,我们在结构和功能上相似的RAD9识别,我们称之为HRAD9B(人)和MRAD9B(小鼠),表明RAD9是基因家族的一部分。我们构建了MRAD9和MRAD9B敲除细胞和小鼠,发现这两个基因对于胚胎发生至关重要。此外,基于RAD9的几个既定功能,例如维持基因组稳定性和同源重组的作用,这对于精子发生至关重要,我们研究了RAD9是否在此过程中起作用。现在,我们提供了新的初步数据,表明我们在早期谱系精子中构建了MRAD9靶向缺失的小鼠,A型A型,实际上这些动物在精子发生中表现出缺陷。该提案的主要重点是基于我们的发现,以研究RAD9功能。具体而言,我们将利用MRAD9基因敲除细胞和我们构建的小鼠来解决旨在阐明基因维持基因组稳定性,促进对DNA损伤的机制的聚焦假设,并调节了精子发生。这些假设包括:1)MRAD9通过调节特定的DNA修复途径和细胞周期检查点来促进基因组稳定性和对DNA损伤的细胞抗性; 2)MRAD9通过调节睾丸中的基因组稳定性,凋亡和修复,在精子发生和减数分裂细胞周期中起重要作用。这些研究将检查从分子到细胞到整个动物水平的MRAD9功能。此外,这项研究可能会影响一系列重要问题,包括了解对DNA损伤的固有易感性,对放射疗法的影响以及对精子发育和男性不育的遗传控制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HOWARD B. LIEBERMAN其他文献

HOWARD B. LIEBERMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HOWARD B. LIEBERMAN', 18)}}的其他基金

ROLE OF RAD9 IN BYSTANDER EFFECTS
RAD9 在旁观者效应中的作用
  • 批准号:
    8281638
  • 财政年份:
    2011
  • 资助金额:
    $ 33.47万
  • 项目类别:
ROLE OF RAD9 IN BYSTANDER EFFECTS
RAD9 在旁观者效应中的作用
  • 批准号:
    7992111
  • 财政年份:
    2010
  • 资助金额:
    $ 33.47万
  • 项目类别:
Variable Dose Rate X-ray Irradiator
可变剂量率 X 射线照射器
  • 批准号:
    7795313
  • 财政年份:
    2010
  • 资助金额:
    $ 33.47万
  • 项目类别:
Rad9-Based Mouse Model of Prostate Carcinogenesis
基于 Rad9 的前列腺癌小鼠模型
  • 批准号:
    7871480
  • 财政年份:
    2009
  • 资助金额:
    $ 33.47万
  • 项目类别:
Rad9-Based Mouse Model of Prostate Carcinogenesis
基于 Rad9 的前列腺癌小鼠模型
  • 批准号:
    7728289
  • 财政年份:
    2009
  • 资助金额:
    $ 33.47万
  • 项目类别:
RADIATION RESEARCH RESOURCE
辐射研究资源
  • 批准号:
    7669925
  • 财政年份:
    2008
  • 资助金额:
    $ 33.47万
  • 项目类别:
Mechanisms of Radioresistance and Cell Cycle Progression
放射抗性和细胞周期进展的机制
  • 批准号:
    8115777
  • 财政年份:
    2007
  • 资助金额:
    $ 33.47万
  • 项目类别:
Mechanisms of Radioresistance and Cell Cycle Progression
放射抗性和细胞周期进展的机制
  • 批准号:
    7902036
  • 财政年份:
    2007
  • 资助金额:
    $ 33.47万
  • 项目类别:
Mechanisms of Radioresistance and Cell Cycle Progression
放射抗性和细胞周期进展的机制
  • 批准号:
    7386915
  • 财政年份:
    2007
  • 资助金额:
    $ 33.47万
  • 项目类别:
Mechanisms of Radioresistance and Cell Cycle Progression
放射抗性和细胞周期进展的机制
  • 批准号:
    7667330
  • 财政年份:
    2007
  • 资助金额:
    $ 33.47万
  • 项目类别:

相似国自然基金

面向掌纹识别的安全与隐私保护理论和方法研究
  • 批准号:
    62376211
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
微观市场均衡视角下中国长期护理保险试点的福利分析与政策评估
  • 批准号:
    72304093
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
面向康复护理机器人的人机信任度评估方法与任务影响机制研究
  • 批准号:
    62306195
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
基于生命质量的癌症患者心理行为与护理干预
  • 批准号:
    72381240026
  • 批准年份:
    2023
  • 资助金额:
    20 万元
  • 项目类别:
    国际(地区)合作与交流项目
天然水体中药品和个人护理品间接光降解产物预测模型的构建和应用
  • 批准号:
    42307496
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention
使用新型 MHealth 干预措施针对年轻人中酒精与阿片类药物的同时使用
  • 批准号:
    10456380
  • 财政年份:
    2023
  • 资助金额:
    $ 33.47万
  • 项目类别:
Engineered tissue arrays to streamline deimmunized DMD gene therapy vectors
工程组织阵列可简化去免疫 DMD 基因治疗载体
  • 批准号:
    10724882
  • 财政年份:
    2023
  • 资助金额:
    $ 33.47万
  • 项目类别:
Enhancing Hypnotic Medication Discontinuation in Primary Care through Supervised Medication Tapering and Digital Cognitive Behavioral Insomnia Therapy
通过监督药物逐渐减量和数字认知行为失眠治疗,加强初级保健中催眠药物的停药
  • 批准号:
    10736443
  • 财政年份:
    2023
  • 资助金额:
    $ 33.47万
  • 项目类别:
A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors
减少年轻成年睾丸癌幸存者不良后果的生物行为干预
  • 批准号:
    10736501
  • 财政年份:
    2023
  • 资助金额:
    $ 33.47万
  • 项目类别:
MIND Foods and Aerobic Training in Black Adults with HTN: An ADRD Prevention Pilot RCT (MAT)
MIND 食品和患有 HTN 的黑人成人的有氧训练:ADRD 预防试点随机对照试验 (MAT)
  • 批准号:
    10585366
  • 财政年份:
    2023
  • 资助金额:
    $ 33.47万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了